AlphaDetect

AlphaDetect is a specialized biotechnology company focused on the early and accurate diagnosis of neurodegenerative diseases, particularly synucleinopathies such as Parkinson's disease and Lewy body dementia. The company utilizes a proprietary Seed Amplification Assay (SAA) platform to detect pathological alpha-synuclein aggregates in cerebrospinal fluid and other biological samples with high sensitivity and specificity. By identifying these molecular hallmarks before the onset of significant clinical symptoms, AlphaDetect enables earlier intervention and supports the development of targeted therapies. Their services are primarily utilized by clinical researchers, pharmaceutical companies for clinical trial stratification, and specialized neurology practices.